Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | TFEB | P19484 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13389343 | 1.00 | LMNA (0.46) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL20824829 | 0.89 | MAOB (0.42) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL22848333 | 0.86 | LMNA (0.43) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL29671313 | 0.86 | LMNA (0.43) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL5474595 | 0.85 | LMNA (0.53) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL5474591 | 0.85 | LMNA (0.53) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL13299432 | 0.83 | KDM4E (0.47) | LMNAHTTCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5457635 | 0.80 | CA1 (0.51) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL11833864 | 0.80 | MAPT (0.59) | LMNACYP3A4SLC6A2HTTNR1I2 | |
| SCHEMBL5468473 | 0.80 | LMNA (0.49) | LMNACYP3A4SLC6A2HTTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | LMNA 2161/4885CYP3A4 2979/4885SLC6A2 3155/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | LMNA 4205/4885CYP3A4 351/4885SLC6A2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.